Epoetin alfa biosimilar (rhEPO) — Indian WHO-GMP cold-chain supply for CKD anaemia, chemotherapy-induced anaemia and post-transplant haematology.

Pre-filled syringes (PFS) at 2,000 IU/0.5mL, 4,000 IU/0.4mL, 6,000 IU/0.6mL, 10,000 IU/1mL and 40,000 IU/1mL (the high-dose oncology / weekly-CKD line), plus 10,000 IU/mL multi-dose vial. PFS is the dominant format in NHS, GCC and EU markets (single-use, no preservative); multi-dose vials remain common in lower-resource African public-sector dialysis where per-IU economics dominate. SC dose is typically 50-75% of IV dose for the same Hb target. All formats ship under validated 2-8°C cold-chain — do not freeze, do not shake, protect from light.

Yes. Biosimilar epoetin alfa has been the NHS preferred-source ESA on the national framework agreement since 2018, with biosimilar uptake driven by NHS England commissioning policy across all adult renal units and satellite dialysis units. M Care partner-line biosimilar dossiers are prepared for MHRA recognition with full EMA-aligned comparability data — analytical fingerprint, in-vitro UT-7 bioassay, in-vivo normocythaemic-mouse reticulocyte response, and Phase III clinical equivalence data versus reference Eprex / Procrit. Where the framework supplier cannot fill, the MHRA Specials / named-patient import route is available — see named-patient import, UK.

Pure red cell aplasia is the most feared adverse event of ESA therapy — anti-erythropoietin neutralising antibodies cause transfusion-dependent anaemia requiring immunosuppression. The historical PRCA cluster (1998-2003) was associated with the Eprex SC formulation in pre-dialysis CKD patients, attributed to uncoated rubber stopper leachables plus room-temperature excursions promoting protein aggregation. M Care partner-line formulations are HSA-free with coated stoppers consistent with current EMA / WHO biosimilar guidance, and the validated 2-8°C cold-chain (do not freeze, do not shake) is treated as PRCA-relevant manufacturing and handling control — not a gentle suggestion. Destination-language SmPC carries the PRCA monitoring patient card, the requirement to investigate any sudden Hb fall on ESA therapy, and the lot-traceability requirement per EMA biosimilar PV expectations.

The UK (NHS biosimilar preferred-source framework supply or named-patient / MHRA Specials route during shortage), the GCC (UAE, Saudi Arabia, Kuwait, Oman, Qatar, Bahrain) through licensed local importers — dialysis-unit and oncology-formulary tenders are the main channels — sub-Saharan Africa (Nigeria, Kenya, Ghana, South Africa, Ethiopia, Tanzania, Uganda, Rwanda) for public-sector dialysis-unit and teaching-hospital nephrology + haematology supply with WHO PQ biotherapeutic pathway support. Germany under §72 AMG (where biosimilar epoetin uptake is among the highest in EU at >80% of new-patient starts), France under ANSM-equivalent route, Brazil (ANVISA), Mexico (COFEPRIS) and the Philippines (FDA Philippines). M Care does not hold US FDA or Australian TGA registrations on this molecule and does not supply into those markets. We do not supply into India. Full market coverage is at markets.

Every consignment ships with a batch-specific Certificate of Analysis (specific activity by in-vivo bioassay per Ph.Eur., protein content, isoform profile by IEF, aggregates by SEC-HPLC, glycan profile, host-cell-protein and host-cell-DNA residuals, bacterial endotoxin, sterility, pH, osmolality, sub-visible particulates), Method of Analysis, biosimilar comparability addendum, Certificate of Pharmaceutical Product (CoPP), WHO-GMP certificate, manufacturing licence, WHO PQ biotherapeutic pathway documentation where applicable, Certificate of Origin (chamber-attested), destination-language pack insert with KDIGO target Hb 100-115 g/L prescribing reminder + PRCA monitoring patient card + 2-8°C cold-chain handling iconography + oncology Hb-target restrictions per NCCN / ESMO + pre-operative thromboembolism warning, plus full 2-8°C cold-chain temperature logs from pre-dispatch through on-arrival. PV contact nominated on registration with biosimilar lot-traceability per EMA / MHRA expectations.

Yes. Full CTD biosimilar dossiers are available against a non-disclosure agreement, for registration with MHRA, GCC central registration, SFDA, MoHAP, NAFDAC, PPB, SAHPRA, EFDA, TMDA, NDA, BfArM, ANSM, ANVISA, COFEPRIS, FDA Philippines and comparable bodies. Module 2 summaries and Module 1 administrative sections are prepared in destination-specific format. Module 3.2.R biosimilar comparability data is the central regulator question for biotherapeutics — analytical fingerprint, in-vitro UT-7 bioassay, in-vivo normocythaemic-mouse reticulocyte response, and Phase III clinical equivalence versus reference Eprex / Procrit in CKD anaemia. Lead time on a biosimilar dossier against a new registration is typically 8-14 weeks from NDA signature (longer than small-molecule because of comparability-data assembly). WHO PQ biotherapeutic dossier prepared separately for African public-sector procurement qualification. See dossier preparation.

For registered markets with stock on hand, dispatch is typically 7-14 working days from confirmed order (longer than small-molecule because of cold-chain qualified-shipper preparation and bioassay-batch QC release). For tender awards (NUPCO, KEMSA, SAHPRA, CMS Ghana, EPSS), the lead time is set in the tender award document. For UK NHS named-patient supply with urgency flagged, validated cold-chain air-freight out of Mumbai can be on a flight within 96 hours. Made-to-order biosimilar batches run 12-20 weeks inclusive of bioassay QC release, biosimilar comparability data and destination artwork. Epoetin alfa requires 2-8°C cold-chain throughout — validated qualified shippers (PCM / phase-change-material or active-cooled depending on lane and transit time), 24/7 in-transit temperature logger on every consignment, on-arrival inspection with photographic seal-integrity and logger-download evidence to the receiving pharmacy. Do not freeze. Do not shake. Protect from light. Temperature-deviation procedure documented and any excursion archived against batch for the full shelf life.